What are some key cancer drugs developed by Novartis?
Among the most notable cancer drugs developed by Novartis are Gleevec (imatinib), Kisqali (ribociclib), and Kymriah (tisagenlecleucel). Gleevec is used to treat chronic myeloid leukemia (CML) and has revolutionized the management of this disease. Kisqali is a CDK4/6 inhibitor used in combination with other therapies for the treatment of HR-positive, HER2-negative breast cancer. Kymriah is a CAR-T cell therapy for certain types of blood cancers, including acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL).
